摘要
目的:评价口服非诺贝特治疗糖尿病视网膜病变(DR)的有效性及安全性。方法:检索PubMed、Cochrane Library、CKNI、万方等数据库中从建库至2020年5月20日关于口服非诺贝特预防及治疗DR的随机对照试验(RCTs)。对选取的文献进行严格的质量分析后,运用Revman 5.3软件对所提取的数据进行分析。结果:本研究共纳入7项RCTs(n=16712)。Meta分析结果显示,与对照组相比,口服非诺贝特首次需要激光治疗的次数明显减少(OR=0.68,95%CI:0.56~0.81,P<0.0001),并有效延缓DR进展(OR=0.71,95%CI:0.59~0.87,P=0.0007),此外,两组在视力改善方面无明显差异(OR=0.98,95%CI:0.86~1.11,P=0.72)。结论:非若贝特可有效减少首次激光治疗的需求,并有效延缓DR的进展。
Objective:To assess the efficacy and safety of fenofibrate for diabetic retinopathy(DR).Methods:Randomized controlled trials(RCTs)of oral fenofibrate for the prevention and treatment of diabetic retinopathy(DR)was retrieved from PubMed,Cochrane Library,CKNI,Wanfang database with the deadline to May 20,2020.The quality of selected studies were strictly evaluated,and the data analyses were performed by Revman 5.3 software.Results:There were 7 RCTs including 16712 cases enrolled.The results of meta-analysis indicated that oral fenofibrate decreased the number of laser treatment required for the first time(OR=0.68,95%CI:0.56 to 0.81,P<0.0001),and alleviated the progression of DR effectively(OR=0.71,95%CI:0.59 to 0.87,P=0.0007),when compared with the control group.In addition,there was no significant difference in vision improvement between the two groups(OR=0.98,95%CI:0.86 to 1.11,P=0.72).Conclusion:Fenofibrate could effectively reduce the need of laser treatment for the first time,and slow down the development of DR.
作者
陈丽华
熊梦婷
郑涛
李奇
Chen Lihua;Xiong Mengting;Zheng Tao;Li Qi(Department of Ophthalmic Optics,Yichang Central People's Hospital,The First College of Clinical Medical Science,China Three Gorges University,Yichang 443003,China;Department of Cardiology,Yichang Central People's Hospital,The First College of Clinical Medical Science&Institute of Cardiovascular Diseases,China Three Gorges University,Yichang 443003,China)
出处
《巴楚医学》
2020年第3期84-89,共6页
Bachu Medical Journal
基金
宜昌市医疗卫生科研项目(No:A17-301-17)。
